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Tumor necrosis factor (TNF) antagonists are efficacious in the treatment of various autoimmune diseases. Two
classes of TNF antagonists are currently commercially available: soluble TNF receptor-Fc fusion proteins
(etanercept) and anti-TNF mAbs (adalimumab and infliximab). The classes differ in molecular structures and
mechanisms of action. The interactions between TNF antagonists with TNF molecules were characterized. The
anti-TNF mAbs, but not the soluble TNF receptor, formed visible lines of precipitation in Ouchterlony assays.
The molecular weights of complexes formed by TNF (52 kDa) with either etanercept (130 kDa), adalimumab
(150 kDa), or infliximab (average 165 kDa) were determined by size exclusion chromatography-light-scattering
assays. Etanercept and TNF formed complexes of 180 and 300 kDa, representing one and two etanercept
monomers bound to a TNF trimer, respectively. Adalimumab and infliximab formed a variety of complexes with
TNF with molecular weights as high as 4,000 and 14,000 kDa, respectively, suggesting the presence of complexes
with a wide range of sizes and stoichiometries. The absence of large complex formation with the binding of
soluble receptor-fusion proteins to TNF may account for the different clinical efficacy and safety profiles of the
two classes of TNF antagonists.
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INTRODUCTION
Biologic therapies that target the proinflammatory cytokine
tumor necrosis factor (TNF) have been shown to be
efficacious in the treatment of several autoimmune diseases,
including moderate to severe plaque psoriasis, moderate to
severe rheumatoid arthritis, and psoriatic arthritis (Nash and
Florin, 2005; Trent and Kerdel, 2005) (Enbrels (etanercept)
prescribing information; (2006). Immunex Corporation;
Humiras (adalimumab) prescribing information (2005) Ab-
bott Laboratories; Remicades (infliximab) prescribing infor-
mation (2006) Centocor Inc.). Some, but not all of the TNF
antagonists are also effective in the treatment of granuloma-
tous diseases, such as Crohn’s disease and Wegener’s
granulomatosis (Targan et al., 1997; Mukhtyar and Luqmani,
2005; Nash and Florin, 2005; Hanauer et al., 2006). There
are currently two classes of marketed biologic drugs that
reduce TNF bioavailability: soluble TNF receptor-Fc fusion
proteins (etanercept) and anti-TNF mAbs (adalimumab and
infliximab).
Despite their common target, the two classes of agents
differ markedly in molecular structure and mechanism of
action (Calabrese, 2003). The anti-TNF mAbs bind TNF with
high avidity, dissociate slowly, and have a long serum half-
life (Scallon et al., 2002; Nestorov, 2005). The soluble TNF
receptor also binds TNF with high avidity, but reversibly and
rapidly dissociates from TNF and has a shorter serum half-life
(Scallon et al., 2002; Nestorov, 2005). All three of the
currently available TNF antagonists bear the Fc portion of
human IgG1. Fc is a structural component of the mAbs,
whereas it is genetically fused to the soluble receptor.
The biochemical nature and ability to form large protein
complexes by a biologic agent that contains an Fc sequence
may have profound impact on Fc-mediated functions. We
investigated the interactions between the currently available
TNF antagonists and their target, TNF.
RESULTS
Differences in diffusion characteristics between soluble recep-
tors and mAbs
In Ouchterlony double-diffusion assays, all of the agents
formed detectable immunoprecipitates with antibodies direc-
ted against the Fc components (Figure 1). Similarly, interac-
tions between the anti-TNF mAb and TNF resulted in the
formation of large, precipitable complexes. In contrast,
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etanercept-TNF complexes did not form precipitation lines in
agarose gels.
Physical properties and stoichiometry of TNF-etanercept com-
plexes
The molecular weights of etanercept, TNF, and TNF-
etanercept complexes were determined by size exclusion
chromatography-light scattering (SEC-LS). Etanercept and
TNF trimers (TNFt) were calculated to be 130 and 52 kDa,
respectively (Table 1).
Etanercept was found to exist in two distinct stable
complexes with TNF (Table 1 and Figure 2). Complex I
consisted of one etanercept molecule bound to a single TNFt,
with an apparent molecular weight of 180 kDa, which
formed when TNF was in excess. Two etanercept molecules
bound to a single TNFt comprised Complex II, which had a
molecular weight of 300 kDa and formed when etanercept
was in excess.
Differences in complex formation with TNF between soluble
receptors and mAbs
Both adalimumab (Figure 3) and infliximab (Figure 4) formed
large protein complexes with TNF, as determined by SEC-LS
analysis. The molecular weight of adalimumab- and inflix-
imab-TNF complexes ranged up to 4,000 and 14,000 kDa,
respectively. In contrast, etanercept did not form large
complexes with TNF (Figure 5).
Table 1. Physical properties of etanercept, TNF and
complexes
MW (kDa) Rh (nm)
Etanercept 130 7.1
TNFt 52 3.1
Etanercept-TNFt complex I 180 6.8
Etanercept2-TNFt complex II 300 9.1
Etanercept2, two etanercept molecules; MW, molecular weight; Rh,
hydrodynamic radius; TNFt, tumor necrosis factor trimer.
Adalimumab Adalimumab
Infliximab Infliximab
Etanercept Etanercept
Goat anti-Fc
antibody TNF
**
Figure 1. Precipitation of protein complexes formed by TNF antagonists and
TNF. Samples were applied to rosette wells of Ouchterlony agarose gels, with
control or test samples in the center wells and TNF antagonists in the outside
wells. The left panel represents control reactions between the TNF antagonists
and anti-Fc antibodies, and the right panel shows the interactions between the
TNF antagonists and TNF. *Precipitation lines.
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Figure 2. Stoichiometry of etanercept-TNF complexes. Etanercept, TNF, and
mixtures of preincubated etanercept and TNF at ratios of 1:3 and 3:1 were
separated by size exclusion chromatography and the retention time of each
sample was examined. AU¼ absorbance units.
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Figure 3. Analysis of adalimumab-TNF complexes. Adalimumab and a
mixture of adalimumab and TNF (3:1 ratio) were analyzed by SEC-LS. The
lighter lines represent the trace of proteins and complexes absorbing at 280 l.
The heavier lines represent molecular masses of complexes detected by light
scattering.
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Figure 4. Analysis of infliximab-TNF complexes. Infliximab and a mixture of
infliximab and TNF (3:1 ratio) were analyzed by SEC-LS. The lighter lines
represent the trace of proteins and complexes absorbing at 280 l. The heavier
lines represent molecular masses of complexes detected by light scattering.
The red dots represent trace amounts of high-molecular weight aggregates of
infliximab.
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DISCUSSION
The soluble TNF receptor, etanercept, did not form large
precipitable complexes with TNF in Ouchterlony double-
diffusion assays; in contrast, interactions between the anti-
TNF mAbs and TNF led to the formation of large complexes.
The mAbs typically do not form precipitable complexes in
these types of assays, as they all bind to the same portion of
the target molecule. Our data therefore suggest that the anti-
TNF mAbs crosslinked via TNF to form the precipitates seen
in the double-diffusion assays. Experiments to further
elucidate the binding characteristics of the TNF antagonists
to TNF were subsequently performed.
Using SEC-LS methodology, the molecular weight of
etanercept was found to be 130 kDa. In agreement with
published studies, TNF was found to exist as a trimer (TNFt)
with a molecular weight of 52 kDa (Eck and Sprang, 1989).
Etanercept was determined to form two types of complexes
with TNFt: as a single molecule bound to a single TNFt
(Complex I) or as two etanercept molecules bound to a single
TNFt (Complex II). Infliximab has been shown to bind to both
monomeric TNF and TNFt (Scallon et al., 2002). Although
adalimumab (150 kDa) is similar in size to etanercept
(130 kDa), this anti-TNF mAbs formed various complexes
up to a molecular weight of 4,000 kDa, representing
numerous stoichiometries.
The SEC-LS analyses of the complexes formed between the
TNF antagonists and TNF were consistent with the results of
the immunodiffusion assays. Etanercept, which failed to
immunoprecipitate TNF in double-diffusion assays, formed
small complexes with TNF in SEC-LS analyses. In contrast,
the anti-TNF mAbs formed large complexes in both analyses.
Based on the size of the etanercept-TNF complexes and the
lack of immunoprecipitation, we hypothesize that the
flexibility of etanercept is more restricted, possibly resulting
in some steric hindrance that prevents crosslinking of
multiple TNFt. The observation that the hydrodynamic radius
of etanercept-TNF Complex I was smaller than the hydro-
dynamic radius of etanercept alone suggests that this
complex is particularly compact in nature. The flexibility of
the mAbs apparently allowed crosslinking of several anti-
bodies to a soluble TNFt.
Activation of complement-dependent cytotoxicity (via the
classical complement pathway) or antibody-dependent cel-
lular cytotoxicity (via Fcg receptors) requires multiple Fc
regions in close physical proximity to each other (Segal et al.,
1983). Thus, large complexes may allow crosslinking of the
Fcg receptors and increased binding to C1q, which may lead
to antibody-dependent cellular cytotoxicity and complement-
dependent cytotoxicity, respectively, in vivo. Adalimumab
(Humiras (adalimumab) prescribing information (2005)
Abbott Laboratories) and infliximab (Remicades (infliximab)
prescribing information (2006) Centocor Inc.) have been
shown to lyse TNF-expressing cells in vitro.
The major differences between the actions of the two
classes of drugs in vivo appear to be related to effects on
granulomatous diseases and infections. Both adalimumab
and infliximab are efficacious in the treatment of Crohn’s
disease (Targan et al., 1997; Hanauer et al., 2006), and
infliximab has been used in the treatment of Wegener’s
granulomatosis, (Mukhtyar and Luqmani, 2005) whereas
etanercept has not demonstrated clinical benefits in these
diseases. Another example of evidence for differences in
mechanisms of action is the observation that patients with
rheumatoid arthritis can be effectively switched from
etanercept therapy to treatment with mAbs, and vice versa,
with clinical benefit (Gomez-Reino and Carmona, 2006).
Although all of the drugs target TNF, the interactions with
TNF and subsequent effector mechanisms may differ suffi-
ciently to allow a patient who is non-responsive to one drug
to respond to the other class of TNF antagonists.
TNF is an important mediator in the immune response to
granulomatous infections, and total blockade of this inflam-
matory cytokine has been postulated to be detrimental
(Nestorov, 2005). It has been reported that the anti-TNF
mAbs may be cytotoxic to TNF-producing cells) (Humiras
(adalimumab) prescribing information (2005) Abbott Labora-
tories and Remicades (infliximab) prescribing information
(2006) Centocor Inc.) by inducing antibody-dependent
cellular cytotoxicity (Scallon et al., 1995), complement-
dependent cytotoxicity (Scallon et al., 1995), or apoptosis
(Scallon et al., 2002; Shen et al., 2005a, b, 2006), which may
explain clinical differences between soluble receptors and
mAbs (Haraoui, 2005). Further studies are required to
determine the ramifications of these functional differences
between the TNF antagonists observed in this study. The
observed differences may help to explain differences in
clinical efficacy and safety (Wallis et al., 2004a, b, 2005).
MATERIALS AND METHODS
Reagents
Etanercept (Enbrels; Amgen Inc., Thousand Oaks, CA) (Enbrels
(etanercept) prescribing information. (2006). Immunex Corporation)
was supplied in a buffer containing 25 mM sodium phosphate, 25 mM
L-arginine, 98 mM sodium chloride, and 1% sucrose. Adalimumab
(Humiras; Abbott Laboratories, North Chicago, IL) (Humiras
(adalimumab) prescribing information (2005) Abbott Laboratories)
was supplied in 105 mM sodium chloride, 5.5 mM monobasic sodium
phosphate dihydrate, 8.6 mM dibasic sodium phosphate dihydrate,
1 mM sodium citrate, 6.2 mM citric acid monohydrate, 66 mM
1.0 × 106
1.0 × 105
10 × 104
16.0 20.0 24.0
Time (minutes)
28.0 32.0
M
ol
ar
 m
as
s 
(g/
mo
l)
Etanercept
Etanercept
130 kDa
(Etanercept)2 TNF
Etanercept + TNF
300 kDa
Figure 5. Analysis of etanercept-TNF complexes. Etanercept and a mixture of
etanercept and TNF (3:1 ratio) were analyzed by SEC-LS. The lighter lines
represent the trace of proteins and complexes absorbing at 280 l. The heavier
lines represent molecular masses of complexes detected by light scattering.
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mannitol, 0.1% polysorbate 80, pH 5.2. Infliximab (Remicades;
Centocor Inc., Malvern, PA) was supplied in 1.6 mM monobasic
sodium phosphate monohydrate, 3.4 mM dibasic sodium phosphate
dehydrate, 5% sucrose, 0.005% polysorbate 80, pH 7.2. Purified
recombinant TNF was supplied by Amgen Inc.
Ouchterlony double-diffusion assays
The central well of a rosette pattern of wells in a flat-bed agarose-
polyethylene glycol Micro-Ouchterlony plate (MP Biomedicals, LLC,
Aurora, OH) was loaded with a control sample of 10 ml (2 mg/ml)
goat anti-human Fc polyclonal antibodies (Sigma Chemical Co, St
Louis, MO) or 10 ml (0.89 mg/ml) recombinant human TNF. Samples
of TNF antagonists (10 ml at 1.00–1.68 mg/ml) were applied to wells
surrounding the center wells, and allowed to diffuse at 371C for
4 hours in humid conditions, then at room temperature for 6 hours.
The Micro-Ouchterlony plate was removed from the case and
incubated under water at room temperature for 3 hours with several
changes of water. Protein complexes formed by interactions between
drug and control or target was visualized by staining the gels with
Coomassie R250 dye and destaining (Invitrogen Corporation,
Carlsbad, CA).
SEC-LS
Samples of individual TNF antagonists (100 mg) or mixtures of
individual TNF antagonists with different molar ratios of TNF (1:3 or
3:1) were preincubated at 41C for 16 hours or 371C for 30 minutes to
16 hours and then applied to HPLC columns for separation by size.
Experiments were performed on an Agilent 1100 HPLC system with
a Superdex-200 gel filtration column (Amersham Pharmacia,
Waukesha, WI). The samples were then passed through a Wyatt
miniDawn LS laser light-scattering detector and Wyatt Optilab DSP
Refractometer (Wyatt Technology Co, Santa Barbara, CA) to
determine the molecular mass and radius of the protein complexes.
Phosphate-buffered saline (2.67 mM potassium chloride, 138 mM
sodium chloride, 1.47 mM potassium phosphate monobasic, 8.1
mM sodium phosphate dibasic, pH 7.4) was used as the mobile
phase at 0.4 ml/minute. To confirm the results and to determine the
hydrodynamic radius, additional experiments were also performed
on a GPS solvent/sample module (GPCmax) with a triple detector
array (TDA302, Visotek Co, Houston, TX).
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